156 related articles for article (PubMed ID: 36743988)
1. Development of a Model to Predict Liver Decompensation prior to Transarterial Chemoembolization Refractoriness in Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ferreira-Silva J; Costa-Moreira P; Cardoso H; Liberal R; Pereira P; Macedo G
GE Port J Gastroenterol; 2023 Jan; 30(1):29-37. PubMed ID: 36743988
[TBL] [Abstract][Full Text] [Related]
2. Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Oshita M; Ohkawa K; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2020 Nov; 50(11):1275-1283. PubMed ID: 32812315
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
[TBL] [Abstract][Full Text] [Related]
4. Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria.
Saito N; Nishiofuku H; Sato T; Maeda S; Minamiguchi K; Taiji R; Matsumoto T; Chanoki Y; Tachiiri T; Kunichika H; Marugami N; Tanaka T
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174075
[TBL] [Abstract][Full Text] [Related]
5. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.
Yoo SH; Jang JW; Kwon JH; Jung SM; Jang B; Choi JY
Clin Mol Hepatol; 2016 Dec; 22(4):458-465. PubMed ID: 28081589
[TBL] [Abstract][Full Text] [Related]
6. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma.
Kohla MA; Abu Zeid MI; Al-Warraky M; Taha H; Gish RG
BMJ Open Gastroenterol; 2015; 2(1):e000032. PubMed ID: 26462282
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
8. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
9. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function.
Saito N; Tanaka T; Nishiohuku H; Sato T; Masada T; Matsumoto T; Anai H; Sakaguchi H; Sueyoshi S; Marugami N; Kichikawa K
Hepatol Res; 2020 Oct; 50(10):1176-1185. PubMed ID: 32721060
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.
Kaibori M; Matsushima H; Ishizaki M; Kosaka H; Matsui K; Kariya S; Yoshii K; Sekimoto M
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1217-1224. PubMed ID: 33906315
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
12. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
13. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging.
Byun J; Kim SY; Kim JH; Kim MJ; Yoo C; Shim JH; Lee SS
Acta Radiol; 2021 Dec; 62(12):1548-1558. PubMed ID: 33197329
[TBL] [Abstract][Full Text] [Related]
14. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
Wang TC; An TZ; Li JX; Zhang ZS; Xiao YD
Front Mol Biosci; 2021; 8():633590. PubMed ID: 33816555
[No Abstract] [Full Text] [Related]
16. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
17. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
[TBL] [Abstract][Full Text] [Related]
18. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study.
Yoon JS; Sinn DH; Lee JH; Kim HY; Lee CH; Kim SW; Lee HY; Nam JY; Chang Y; Lee YB; Cho EJ; Yu SJ; Kim HC; Chung JW; Kim YJ; Yoon JH
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31689972
[TBL] [Abstract][Full Text] [Related]
19. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Urabe A; Shigekawa M; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2020 Mar; 50(3):365-373. PubMed ID: 31661722
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
